Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PCV21

Phase 3Biologic

PCV21 is one of 105 biologic programs targeting Immunogenicity. It is currently in Phase 3.

3

Indications

8

Total Trials

8

Active Trials

104

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunogenicityActive, not recruiting

VaccinationActive, not recruiting

Sickle Cell DiseaseRecruiting

ImmunogenicityPhase 3

Active, not recruiting

VaccinationPhase 3

Active, not recruiting

Sickle Cell DiseasePhase 3

Recruiting

Competition

Competitive Landscape

98 competitors in Sickle Cell Disease

#DrugCompanyPhaseTrials

Campath

GGenzyme, a Sanofi Company

Ritalin

Aqvesme

AAgios Pharmaceuticals, Inc.

Toradol

JJavelin Pharmaceuticals

Wayrilz

GGenzyme, a Sanofi Company

Fludara

Cellcept

PIASKY

Tepadina

Jazz Pharmaceuticals

Rapamune

PPrism Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Immunogenicity

NCT06838000

Q1 2027

Phase 3Recruiting

Immunogenicity

NCT07284654

Phase 3Recruiting

Sickle Cell Disease

NCT07247188

Q2 2027

Phase 3Recruiting

Vaccine

NCT06824194

Phase 3Active, not recruiting

Vaccine

NCT06736041

Q3 2027

Phase 3Active, not recruiting

Vaccine

NCT06975878

Clinical

Trials by Indication[1]

Vaccine4 trials

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT06824194·2,320 enrolled

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruiting· Sanofi logo

Sanofi·Phase 3·NCT06736041·1,714 enrolled

Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruiting· Sanofi logo

Sanofi·Phase 3·NCT06975878·1,092 enrolled

Show 1 more trial

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT07348692·896 enrolled

Immunogenicity2 trials

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Recruiting·VVaxcyte, Inc.·Phase 3·NCT07284654·4,000 enrolled

Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

Active, not recruiting· Sanofi logo

Sanofi·Phase 3·NCT06838000·1,268 enrolled

Vaccination1 trial

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruiting· Sanofi logo

Sanofi·Phase 3·NCT06824181·580 enrolled

Sickle Cell Disease1 trial

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT07247188·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for PCV21. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PCV21 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PCV21. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Related News